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ABSTRACT
Background. Preoperative portal vein embolization
(PVE) is frequently used to improve future liver remnant
volume (FLRV) and to reduce the risk of liver failure after
major liver resection.
Objective. This paper aimed to assess postoperative out-
comes after PVE and resection for suspected perihilar
cholangiocarcinoma (PHC) in an international, multicentric
cohort.
Methods. Patients undergoing resection for suspected
PHC across 20 centers worldwide, from the year 2000,
were included. Liver failure, biliary leakage, and hemor-
rhage were classified according to the respective
International Study Group of Liver Surgery criteria. Using
propensity scoring, two equal cohorts were generated using
matching parameters, i.e. age, sex, American Society of
Anesthesiologists classification, jaundice, type of biliary
drainage, baseline FLRV, resection type, and portal vein
resection.
Results. A total of 1667 patients were treated for sus-
pected PHC during the study period. In 298 patients who
underwent preoperative PVE, the overall incidence of liver
failure and 90-day mortality was 27% and 18%, respec-
tively, as opposed to 14% and 12%, respectively, in
patients without PVE (p\ 0.001 and p = 0.005). After
propensity score matching, 98 patients were enrolled in
each cohort, resulting in similar baseline and operative
characteristics. Liver failure was lower in the PVE group
(8% vs. 36%, p\ 0.001), as was biliary leakage (10% vs.
35%, p\ 0.01), intra-abdominal abscesses (19% vs. 34%,
p = 0.01), and 90-day mortality (7% vs. 18%, p = 0.03).
Conclusion. PVE before major liver resection for PHC is
associated with a lower incidence of liver failure, biliary
leakage, abscess formation, and mortality. These results
demonstrate the importance of PVE as an integral com-
ponent in the surgical treatment of PHC.
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Portal vein embolization (PVE) is considered the gold-
standard procedure to enhance the future liver remnant
(FLR) before major liver resection and to reduce the risk of
postoperative liver failure and mortality.1,2 Since its
introduction more than three decades ago, PVE has shown
to induce an increase in FLR volume (FLRV) in both
healthy and compromised liver parenchyma, while asso-
ciated with minimal adverse events.3–5 A decrease in
postoperative liver failure using PVE has frequently been
reported; however, in the only prospective comparative
clinical trial, undertaken by Farges et al. in 2003, PVE
decreased postoperative complications only in patients
with compromised liver parenchyma at increased risk of
liver failure.6
Patients with perihilar cholangiocarcinoma (PHC) are
especially at risk for liver failure due to biliary obstruction
and cholestasis frequently encountered in these patients
and which profoundly compromise the liver’s regenerative
capacity.7,8 The vast majority of these patients require
major liver resection to obtain tumor-free margins, leaving
a small liver remnant that is also not able to efficiently
regenerate. Therefore, biliary drainage is an essential
component in the preoperative work-up of these patients in
order to reduce the risk of adverse events. Liver failure and
mortality rates are reported to be between 17 and 24% and
10 and 14%, respectively, and have remained high in
Western series.9–13
Several studies addressed the use of PVE in patients
with PHC and showed increases in liver volume; however,
comparative studies demonstrating a beneficial effect of
PVE on adverse events after resection are currently lacking
for PHC.14–16 Therefore, this study aimed to evaluate the
effect of PVE on the risk of morbidity and mortality after
resection for PHC in a large multicentric Western cohort.
METHODS
All 20 participating centers included a median of 80
(25–115) consecutive resections for presumed PHC with-
out a required fixed timespan but not preceding the year
2000. Each center included their retrospective series using
a standardized and anonymized data file. PHC was defined
as a suspicious biliary tumor originating at the hepatic duct
confluence between the segmental bile ducts and cystic
duct. For the current study, all patients who had only
undergone excision of the extra hepatic bile ducts, explo-
rative laparotomy, or liver transplantation were excluded.
The need for ethical approval and individual informed
consent was waived by the Institutional Medical Ethics
Committee of the Amsterdam University Medical Center.
Patient Work-Up and Management
The multicenter set-up of the current study inevitably
led to differences in the work-up and management of the
included patients. Therefore, the selection of patients for
PVE and biliary drainage differed between centers. In
general, most patients planned for large liver resections
underwent preoperative, endoscopic, or transhepatic biliary
drainage of at least the FLR.
Outcome Parameters
Preoperative cholangitis was defined as fever and
leukocytosis requiring (additional) biliary drainage in
accordance with the definitions applied in the DROP and
DRAINAGE trials dealing with preoperative biliary drai-
nage.17,18 Major liver resection was defined as resection of
at least three Couinaud liver segments. The liver remnant
volume share (FLRV) was calculated by dividing the
FLRV (in milliliters) by the total liver volume (in milli-
liters) and multiplying by 100%. R0 resection margins
were defined as tumor-free margins in all reported margins
in the respective pathology reports. All complications
within 30 days after surgery were scored and classified
according to the Dindo classification system, with grade III
or higher considered as major morbidity. Liver failure,
biliary leakage, and hemorrhage were scored and classified
according to the respective International Study Group of
Liver Surgery (ISGLS) criteria, and only grades B and C
were considered as clinically relevant.19–21 Perioperative
mortality was defined as death within 90 days after sur-
gery, while overall survival was defined as the time
between surgery and death, or date of last follow-up.
Statistical Analyses
Categorical variables were reported as numbers with
percentages, and tested using Chi square or Fisher’s exact
tests when the expected cell count in a category was\ 5.
Continuous variables were displayed as median with
interquartile range (IQR), and tested using Mann–Whitney
U tests. Propensity score matching was performed using
the psmatching3 plugin for SPSS using nearest-neighbor
matching (1:1) with a caliper of 0.2. Matching parameters
included age, sex, American Society of Anesthesiologists
(ASA) classification, jaundice at presentation, biliary
drainage, baseline FLRV share (before PVE), type of
resection, and concomitant vascular resections. Statistical
analyses were performed using SPSS (IBM Corporation,
Armonk, NY, USA).
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RESULTS
A total of 1667 patients from 20 participating centers
were enrolled. Of these, the following cases were excluded:
37 un-resectable cases, 140 patients with extrahepatic bile
duct resection only, and 6 patients undergoing liver trans-
plantation. The remaining 1484 patients all underwent
combined liver and biliary resection for presumed PHC
(Table 1).
Overall, most patients (90%) suffered from jaundice and
consequently the majority underwent biliary drainage
before surgery (83%), at the expense of preoperative
cholangitis in 22% of patients. The majority of patients
underwent either right (49%) or left (47%) liver resection,
and portal vein reconstruction was performed in 32% of
cases. The overall liver failure rate was 17% and 90-day
mortality was 13%. 94% of patients had a pathology-con-
firmed diagnosis of PHC in the resection specimen, of
whom 66% had tumor-free resection margins.
In this study, 298 (20%) patients underwent PVE before
liver resection (Table 1). There was large variety in the use
of PVE across institutions (Fig. 1a), showing a trend
towards more frequent use in more recent years (Fig. 1b).
The right and left liver segments were embolized in 277
TABLE 1 Baseline and
operative characteristics
PVE (n = 298) No PVE (n = 1186) p Value
Age, years [median (IQR); n = 1484] 64 (56–71) 65 (57–72) 0.302
Male sex (n = 1484) 150 (50) 700 (59) 0.007
ASA classification (n = 1386) 0.574
I 24 (8) 127 (12)
II 155 (54) 554 (50)
III 104 (36) 404 (37)
IV 4 (1) 14 (1)
Jaundice at presentation (n = 1370) 233 (86) 861 (78) 0.001
Baseline bilirubin level [median (IQR); n = 1108] 86 (16–207) 58 (15–171) \ 0.001
Biliary drainage (n = 1370) \ 0.001
None 22 (8) 213 (18)
PTBD 74 (25) 300 (25)
EBD 138 (47) 502 (43)
Both 61 (21) 165 (14)
Preoperative cholangitis (n = 1400) 63 (21) 238 (22) 1.000
Bismuth classification (n = 1452) \ 0.001
Left/right duct 4 (1) 32 (3)
I 16 (6) 41 (4)
II 23 (8) 117 (10)
IIIA 139 (48) 329 (28)
IIIB 12 (4) 367 (32)
IV 95 (33) 277 (24)
Resection type (n = 1484) \ 0.001
Left hemihepatectomy 18 (6) 442 (37)
Extended left hemihepatectomy 3 (1) 233 (20)
Right hemihepatectomy 56 (19) 191 (16)
Extended right hemihepatectomy 221 (74) 265 (22)
Other – 55 (5)
Portal vein reconstruction (n = 1481) 148 (50) 327 (28) \ 0.001
Future liver remnant volume share [median (IQR)]
Baseline (n = 510) 23 (19–29) –
After PVE (n = 131) 33 (27–39) 42 (31–66) \ 0.001
Preoperative bilirubin level [median (IQR); n = 1068] 15 (8–35) 21 (10–44) \ 0.001
Data are expressed as n (%) unless otherwise specified
PVE Portal vein embolization, IQ R interquartile range, ASA American Society of Anesthesiologists, PTBD
percutaneous transhepatic biliary drainage, EBD endoscopic biliary drainage
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(93%) and 21 (7%) patients, respectively. Segment 4
embolization was performed in 16% of all PVE procedures.
In 73%, the embolic material consisted of particles in
combination with coils or a plug; in 23%, glue-like mate-
rials were used; and the remaining 4% of PVE procedures
were performed using a combination of the two. The rates
of PVE were higher among right liver resections (38%,
277/733) compared with left liver resections (3%, 21/696),
and were highest for extended right liver resections (45%,
221/486). The higher rates of biliary drainage, predomi-
nantly larger resections in right (extended) liver resections
and consequently smaller remnant livers, as well as more
frequent portal vein resections, indicate the higher risk of
resections undertaken after PVE compared with resections
without PVE. These risks are confirmed by the outcomes
reported in Table 2 showing more frequent major compli-
cations, liver failure, and higher mortality in PVE patients.
Standard left-liver resections allow for a larger liver
remnant with lower operative risks, rendering PVE not
often necessary in this group of patients. Assessment of the
outcomes after PVE should therefore be related to the type/
extent of resection. When comparing only right (extended)
liver resections, the risks were more equal, with liver
failure and mortality rates of 25% and 19%, respectively, in
the 277 patients with PVE, compared with 23% and 16% in
the 456 patients without PVE (p = 0.473 and p = 0.419);
however, direct comparison of these cohorts is hampered
by the wide selection of patients.
Propensity Score Matched Cohort
In order to be able to analyze the true effects of PVE on
postoperative outcomes, a propensity matched comparison
was performed using only cases with complete data on all
relevant parameters. After exclusion of cases with missing
volume parameters, a total of 510 patients (151 with PVE
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FIG. 1 a Differential use of PVE across institutions with at least 15 included cases. The dotted line represents the use of PVE in the entire
cohort. b Use of PVE per year in the cohort. PVE portal vein embolization
TABLE 2 Postoperative
outcomes
PVE (n = 298) No PVE (n = 1186) p-Value
Pathology diagnosis (n = 1460) 0.830
Perihilar cholangiocarcinoma 279 (95) 1088 (93)
Benign 6 (2) 29 (3)
Other 8 (3) 48 (4)
Tumor-free margin (n = 1417) 185 (64) 745 (66) 0.341
Morbidity Dindo grade III or higher (n = 1474) 177 (59) 520 (44) \ 0.001
Liver failure ISGLS grade B/C (n = 1472) 81 (27) 166 (14) \ 0.001
Biliary leakage ISGLS grade B/C (n = 1475) 59 (20) 248 (21) 0.690
Hemorrhage ISGLS grade B/C (n = 1214) 18 (10) 61 (6) 0.078
Intra-abdominal abscess (n = 1475) 50 (17) 257 (22) 0.127
90-day mortality (n = 1484) 53 (18) 136 (12) 0.005
Data are expressed as n (%)
PVE Portal vein embolization, ISGLS International Study Group of Liver Surgery
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and 359 without) were available for matching. Based on all
parameters relevant for postoperative outcomes, two mat-
ched cohorts of 98 patients were generated (Table 3). The
matched cohorts were equal in all preoperative and oper-
ative variables, including the baseline FLRV share, which
increased a median of 7 percentage points after PVE. The
increase in true remnant liver volume after PVE was 42%
(18–59) in a median of 22 (19–29) days. The use of PVE
was associated with reductions in liver failure (from 36%
to 8%; 4.4-fold reduction) and biliary leakage (from 35 to
10%; 3.5-fold reduction), and a decrease in 90-day mor-
tality (from 18 to 7%; 2.6-fold reduction).
TABLE 3 Propensity score
matched comparison
PVE (n = 98) No PVE (n = 98) p-Value
Age, years [median (IQR)] 65 (57–71) 63 (56–71) 0.606
Male sex 55 (66) 61 (62) 0.468
ASA classification 0.648
I 10 (10) 14 (14)
II 46 (47) 46 (47)
III 42 (43) 38 (39)
Jaundice at presentation 74 (76) 73 (74) 1.000
Baseline bilirubin level [median (IQR)] 60 (15–213) 48 (13–135) 0.384
Biliary drainage 0.601
None 11 (11) 12 (12)
PTBD 34 (35) 26 (27)
EBD 29 (30) 36 (37)
Both 24 (25) 24 (25)
Preoperative cholangitis 28 (29) 24 (25) 0.628
Bismuth classification 0.086
Left/right duct 2 (3) 3 (3)
I 7 (7) 3 (3)
II 7 (7) 17 (17)
IIIA 49 (51) 46 (47)
IIIB 3 (3) 9 (9)
IV 27 (28) 20 (20)
Future liver remnant volume share [median (IQR)] 0.130
Baseline 27 (21–32) –
After PVE 35 (28–42) 29 (23–33) \0.01
Preoperative bilirubin level [median (IQR)] 12 (5–27) 15 (9–38) 0.057
Resection type 0.481
Left hemihepatectomy 2 (2) 5 (5)
Extended left hemihepatectomy 1 (1) 2 (2)
Right hemihepatectomy 35 (36) 28 (29)
Extended right hemihepatectomy 60 (61) 63 (64)
Portal vein resection 18 (18) 21 (21) 0.721
Estimated blood loss [median (IQR)] 775 (500–1300) 900 (600–1996) 0.054
Morbidity Dindo grade III or higher 50 (51) 53 (54) 0.775
Liver failure ISGLS grade B/C 8 (8) 35 (36) \ 0.001
Biliary leakage ISGLS grade B/C 10 (10) 34 (35) \ 0.001
Hemorrhage ISGLS grade B/C 6 (6) 7 (7) 1.000
Intra-abdominal abscess 19 (19) 33 (34) 0.034
90-day mortality 7 (7) 18 (18) 0.031
Data are expressed as n (%) unless otherwise stated
PVE Portal vein embolization, IQR interquartile range, ASA American Society of Anesthesiologists, PTBD
percutaneous transhepatic biliary drainage, EBD endoscopic biliary drainage
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DISCUSSION
This study describes a large Western cohort of combined
hepatic and biliary resections for PHC and included 1484
patients among 20 centers. Overall, 20% of patients
underwent PVE before liver resection, but the use of PVE
varied considerably across centers. The overall postopera-
tive outcomes demonstrated that patients who underwent
PVE were high surgical risks, showing higher rates of
adverse events following resection, but any comparison is
limited by selection. In a propensity score matched anal-
ysis, the effect of PVE on postoperative outcomes was
assessed in two equal cohorts of 98 patients. Although
preoperative parameters were similar, the incidences of
liver failure, biliary leakage, intra-abdominal abscesses,
and postoperative mortality were lower in the PVE group
compared with patients without PVE. These outcomes in
the high-risk patients who underwent PVE were all well
below the rates in the overall cohort, while all rates of the
matched patients without PVE stand well above those in
the entire cohort.
The only prospective trial dealing with PVE showed a
reduction in postoperative morbidity in patients with
compromised liver parenchyma who underwent preopera-
tive PVE; however, this trial included only patients
undergoing standard right hemihepatectomy and no
patients with PHC.6 Specifically in PHC, a study from a
high-volume center in Japan reported a postoperative
mortality rate of 4.5% in 132 patients who underwent PVE
for an anticipated liver remnant of\ 40%, while mortality
was 3.7% in 136 patients who underwent resection of
\ 50% of liver volume without PVE.22 These results
illustrate that PVE reduces operative risks since the former
can be considered high-risk resections compared with
patients with a remnant liver of 50% or higher; however, a
direct comparison was not reported. The current analyses
using a matched cohort of patients with and without PVE
clearly demonstrates a reduction in postoperative rates of
liver failure and mortality.
Although these results confirm the expected risk-re-
ducing effects of PVE before major liver resection, PVE is
only sparsely used in Western series. This is in contrast
with the frequent use of PVE in Eastern series; 23 Eastern
centers often report the use of PVE in the majority of
patients.23–25 The largest single-center series reported use
of PVE in 60% of patients and while the rates of liver
failure were comparable (32%), mortality was substantially
lower at only 2%.25 This remarkable difference in mortality
has been noted across literature 23,26 and could well be due
to the higher rates of PVE used in Eastern centers.12,23
The use of PVE extends the time until resection by at
least 3–6 weeks in order to allow sufficient growth of the
anticipated remnant liver.5 In the interval to surgery, these
patients are at risk of developing cholangitis, which is
associated with high rates of liver failure and mortality
after hepatectomy.11,12,27,28 Cholangitis was not included
as a matching parameter in the current analyses. In the
matched comparison, the incidence of preoperative
cholangitis was similar, suggesting that the increased time
to surgery associated with PVE had little impact on out-
comes. Furthermore, despite similar episodes of
cholangitis, liver failure and mortality were reduced in
patients who underwent PVE, which suggests that the
protective effect of PVE overruled the negative effects of
PVE.11,12 Considering the negative impact of cholangitis
on outcomes, PVE should perhaps be liberally considered
in this subgroup of patients, although direct evidence is
lacking and will likely be difficult to obtain.
The selection of patients with PHC for PVE is a chal-
lenge since the obstructive cholestasis and accompanying
biliary drainage and cholangitis are associated with loss of
remnant liver function, in addition to its size alone.12 The
most frequently used remnant volume cut-off value is
40%,14 but literature is equivocal and liver volume alone
has insufficient predictive value for accurate patient
selection for PVE.12,14,29 Several modalities for functional
assessment of the remnant liver have been proposed to aid
in the decision to perform PVE. Indocyanine green clear-
ance tests have shown added value, over volume alone, to
predict adverse outcomes, however the negative predictive
value that is essential to select patients for PVE is
low.25,30–32 In other words, a value for sufficient liver
function to safely proceed without the need for PVE would
benefit patient selection. Hepatobiliary scintigraphy (HBS)
with technetium-labeled mebrofenin could help to achieve
this goal. The usual cut-off value used in previous publi-
cations has been 2.7% min-1 m-2 based on body surface
area; however, a recent report demonstrated a body surface
area uncorrected remnant liver function of 8.5%/min to be
safe.29 This relatively high cut-off value potentially leads
to high rates of PVE but since complications and adverse
outcomes of PVE are rare, this is likely a valuable
approach to improve outcomes.29,33 Adherence to such
recommendations likely reduces the relatively high liver
failure rates still observed in PHC patients when adhering
to the 2.7% min-1 m-2 cut-off.29
Although 298 patients underwent PVE in the current
cohort, only 98 patients were matched, for several reasons.
First, only patients with complete data, i.e. without any
missing data, were included to ensure high-quality analy-
sis. Due to the relatively low number of patients with data
on liver volumes, which is an essential parameter to assess
operative risks, the number of patients eligible for match-
ing was limited. Second, patients who underwent PVE had
small remnant livers, whereas a low number of patients
with small remnant livers were exposed to resection
P. B. Olthof et al.
without PVE due to the obvious risk of liver failure. This
difference limits the ability to generate a large and well-
matched cohort. Despite these limitations, the current
strategy is likely the most accurate possible and the closest
to a randomized trial, which will obviously not be possible
to set-up because of ethical reasons. The retrospective
study design is another limitation and leaves the study
subject to selection bias. The time required between PVE
and resection can be considered a test of time in the
selection of patients with more favorable tumor biology. In
addition, patients lacking an adequate hypertrophy
response after PVE have likely not been subjected to sur-
gery. Additionally, there may have been differences in
patient selection for PVE as well as criteria to proceed to
surgery, which could have affected the results; however,
randomized studies in PHC are difficult to perform due to
the rarity of the disease. The current cohort was a large
Western multicenter cohort, which improves its reliability.
Eastern centers were deliberately not included in the series
for these analyses due to the differences in management
and outcomes. Future studies should also confirm these
findings in Eastern patients.23,26 Finally, some patients will
have undergone PVE but no resection, however these
patients were not included in this study, which could be a
confounding factor. However, since approximately
37–46% 34–36 of patients are found to be unresectable at
laparotomy regardless of PVE, including these patients
would have resulted in results that would be difficult to
interpret.
CONCLUSION
The propensity score matched comparison in this mul-
ticenter cohort of 1484 patients showed that PVE was
associated with a 4.4-fold reduction in liver failure and a
2.6-fold reduction in 90-day mortality in patients under-
going major liver resection for PHC. These outcomes in
these high-risk patients after PVE are better than the out-
comes in the overall cohort and show that PVE can be
essential for decreasing surgical risk in these patients.
Although the exact indications for PVE in patients with
PHC are not clearly defined, and the use of PVE varies
widely across centers, a liberal approach to the application
of PVE in patients with future livers remnant \ 40% is
likely to improve postoperative outcomes.
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